nach oben

Pediatric Cardiology

Erschienen in:

16.01.2018 | Original Article

Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease?

verfasst von: Seyma Kayali, Ilker Ertugrul, Tamer Yoldas, Ozkan Kaya, Senem Ozgür, Utku A. Orün, Selmin Karademir

Erschienen in: Pediatric Cardiology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

To analyze the role of sensitive cardiac troponin I (scTnI) and high-sensitive troponin T (hscTnT) in the determination of myocardial injury caused by volume and pressure load due to pulmonary hypertension (PH) and to investigate if these markers may be useful in the management of PH in childhood. Twenty-eight patients with congenital heart disease (CHD) with left to right shunt and PH, 29 patients with CHD with left to right shunt but without PH, and 18 healthy children, in total 75 individuals, were included in the study. All cases were aged between 4 and 36 months. Echocardiographic evaluation was performed in all cases, and invasive hemodynamic investigation was performed in 33 cases. Blood samples were obtained from all cases, for the measurement of brain natriuretic peptide (BNP), pro-brain natriuretic peptide (pro-BNP), sensitive cardiac troponin I (scTnI), and high-sensitive troponin T (hscTnT) levels. The mean BNP, pro-BNP, scTnI, and hsTnT levels were statistically significantly higher in patients with PH than in the patients without PH (p < 0.001). A statistically significant positive correlation was determined between pulmonary artery systolic pressure and scTnI and hscTnT levels (r = 0.34 p = 0.01, r = 0.46 p < 0.001, respectively) levels. Pulmonary hypertension determined in congenital heart diseases triggers myocardial damage independently of increased volume or pressure load and resistance, occurring by disrupting the perfusion via increasing ventricular wall tension and the myocardial oxygen requirement. Serum scTnI and hscTnT levels may be helpful markers to determine the damage associated with PH in childhood.

Olguntürk R (2010) Pediatric pulmonary hypertension and pulmonary arterial hypertension secondary to congenital heart diseases. Anadol Kardiyol Derg 10:50–56CrossRef

Lammers AE, Apitz C, Zartner P, Hager A, Dubowy KO, Hansmann G (2016) Diagnostics, monitoring and outpatient care in children with suspected pulmonary hypertension/paediatric pulmonary hypertensive vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102:1–13CrossRef

Haworth SG (2006) The management of children with congenital heart disease. Pulmonary Arterial Hypertension Related to Congenital Heart Disease 1st ed. London

Joshi R, Kalra R, Kumar N, Aggarwal N (2016) Critical decision of operability in congenital heart disease patient with severe pulmonary hypertension. Ann Card Anaesth 19:744CrossRefPubMedPubMedCentral

Apitz C, Hansmann G, Schranz D (2016) Hemodynamic assessment and acute pulmonary vasoreactivity testing in the evaluation of children with pulmonary vascular disease. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102:23–29CrossRef

Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A (2006) Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 48:2546–2552CrossRefPubMed

Pattathu J, Gorenflo M, Hilgendorff A, Koskenvuo JW, Apitz C, Hansmann G, Alastalo TP (2016) Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102:36–41CrossRef

Pezzuto B, Badagliacca R, Poscia R, Ghio S, D’Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD (2015 Mar) Circulating biomarkers in pulmonary arterial hypertension: update and future direction. J Heart Lung Transplant 34:282–305CrossRefPubMed

Yilmaz MB, Zorlu A, Dogan OT, Karahan O, Tandogan I, Akkurt I (2011) Role of CA-125 in identification of right ventricular failure in chronic obstructive pulmonary disease. Clin Cardiol 34:244–248CrossRefPubMed

10.

Oguz MM, Oguz AD, Sanli C, Cevik A (2014) Serum levels of soluble ICAM-1 in children with pulmonary artery hypertension. Tex Heart Inst J 4:159–164CrossRef

11.

Yıldırım A, Güzelmeriç F, Öner CN, Karaağaç AT, Şaşmazel A, Erdem H, Özdemir O, Baysal A (2014) Prognostic significance of sICAM-1 and sVCAM-1 molecules for cardiac surgery in pediatric patients with pulmonary hypertension. Anadolu Kardiyol Derg 14:274–279PubMed

12.

Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG, Plein S, Mueller C, Haaf P (2017) Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med 12:147–155CrossRefPubMedPubMedCentral

13.

Hafez MO, Morsy SM, Mahfoz RA, Ali AR (2015) Myocardial injury in children with unoperated congenital heart diseases. Cardiol Res Pract. https://doi.org/10.1155/2015/104818 PubMedPubMedCentral

14.

Torbicki A, Kurzyna M, Kuca P, Fijałkowska A, Sikora J, Florczyk M et al (2003) Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation 108:844–848CrossRefPubMed

15.

Antman EM (2002) Decision making with cardiac troponin tests. N Engl J Med 346:2079–2082CrossRefPubMed

16.

Mair J (2014) High-sensitivity cardiac troponins in everyday clinical practice. World J Cardiol 6:175–182CrossRefPubMedPubMedCentral

17.

Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M et al (2003) Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 57(4):191–197PubMed

18.

Bader D, Kugelman A, Lanir A, Tamir A, Mula E, Riskin A (2006) Cardiac troponin I serum concentrations in newborns: a study and review of literature. Clin Chin Acta 371(1–2):61–65CrossRef

19.

Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F et al (2013) Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. J Am Soc Echocardiogr 26:1–14CrossRefPubMed

20.

Apple FS, Wu AHB, Jaffe AS (2002) European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J 144:981–986CrossRefPubMed

21.

Apple FS, Wu AHB (2001) Myocardial infarction redefined: role of cardiac troponin testing. Clin Chem 47:377–379PubMed

22.

Antman EM, Tanasijevic MJ, Thompson B et al (1996) Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Eng J Med 335:1342–1349CrossRef

23.

Venge P, Langerquist B, Diderholm E et al (2002) On behalf of the FRISC II Study Group. Clinical Performance of three cardiac troponin assays in patients with unstable coronary artery disease (FRISC II substudy). Am J Cardiol 89:1035–1041CrossRefPubMed

24.

Özhan H, Albayrak S, Uzun H,et al (2007) Correlation of plasma B Type natriuretic peptide with shunt severity in patients with atrial or ventricular septal defect. Pediatr Cardiol 28:272–275CrossRefPubMed

25.

Holmström H, Hall C, Thaulow E (2001) Plasma levels of natriuretic peptides and hemodynamic assessment of patent ductus arteriosus in preterm infants. Acta Paediatr 90:184–191CrossRefPubMed

26.

Leuchte HH, Holzapfel M, Baumgartner RA et al (2005) Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 128:2368–2374CrossRefPubMed

27.

Fijalkowska A, Kurzyna M, Torbicki A et al (2006) Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 129:1313–1321CrossRefPubMed

28.

Conen D, Pfisterer M, Martina B (2006) Substantial intraindividual variability of BNP concentrations in patients with hypertension. J Hum Hypertens 20:387–391CrossRefPubMed

29.

Takatsuki S, Wagner BD, Ivy D (2012) B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension. Congenit Heart Dis 7(3):259–267CrossRefPubMedPubMedCentral

30.

Bernus A, Wagner BD, Accurso F et al. (2009) Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. Chest 135(3):745–751CrossRefPubMed

31.

Galie N, Manes A, Palazzini M et al (2008) Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s syndrome. Drugs 68:1049–1066CrossRefPubMed

32.

Kubo T, Kitaoka H, Okawa M et al (2010) Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin Cardiol 33:E1–E7CrossRefPubMed

33.

Petersen SE, Jerosch-Herold M, Hudsmith LE et al (2007) Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115:2418–2425CrossRefPubMed

34.

Galderisi M (2007) Epicardial coronary vessels and coronary microcirculation in pressure overload hypertrophy: a complex interaction. Am J Hypertens 20:285–286.CrossRefPubMed

35.

Apple FS (2009) A new season for cardiac troponin assays: it’s time to keep a scorecard. Clin Chem 55:7 1303–1306PubMed

36.

Xu RY, Zhu XF, Yang Y, Ye P (2013) High-sensitive cardiac troponin T. J Geriatr Cardiol 10:102–109PubMedPubMedCentral

37.

Colvin KL, Dufva MJ, Delaney RP, Ivy DD, Stenmark KR, Yeager M (2014) Biomarkers for pediatric pulmonary arterial hypertension—a call to collaborate. Front Pediatr 2:1–12CrossRef

38.

Zelniker T, Uhlmann L, Spaich S, Friedrich J, Preusch MR, Meyer FJ et al. (2015) Novel biomarkers for risk stratification in pulmonary arterial hypertension. ERJ Open Res 1:00008-2015CrossRefPubMedPubMedCentral

39.

Eggers KM, Lindahl B (2017) Application of cardiac troponin in cardiovascular diseases other than acute coronary syndrome. Clin Chem 63:223–235CrossRefPubMed

40.

Sugimoto M, Ota K, Kajihama A, Nakau K et al (2011) Volume overload and pressure overload due to left-to-right shunt- induced myocardial injury: evaluation using a highly sensitive cardiac troponin I assay in children with congenital heart disease. Circ J 75:2213–2219CrossRefPubMed

41.

Eerola A, Jokinen EO, Savukoski TI et al (2013) Cardiac troponin I in congenital heart defects with pressure or volume overload. Scand Cardiovasc J 47:154–159CrossRefPubMed

42.

Filusch A, Giannitsis E, Katus HA, Meyer FJ (2010) High-sensitive troponin T: a novel biomarker for prognosis and disease severity in patients with pulmonary arterial hypertension. Clin Sci 119:207–213CrossRefPubMed

43.

Apple FS (1999) Clinical and analytical standardization ıssues confronting cardiac troponin I. Clin Chem 45(1):18–20PubMed

44.

Labugger R, Organ L, Collier C et al (2000) Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 102:1221–1226CrossRefPubMed

45.

Tate JR, Heathcote D, Rayfield J, Hickman PE (1999) The lack of standardization of cardiac troponin I assay systems. Clin Chim Acta 284:141–149CrossRefPubMed

Titel: Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease?
verfasst von: Seyma Kayali
Ilker Ertugrul
Tamer Yoldas
Ozkan Kaya
Senem Ozgür
Utku A. Orün
Selmin Karademir
Publikationsdatum: 16.01.2018
Verlag: Springer US
Erschienen in: Pediatric Cardiology / Ausgabe 4/2018
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-018-1811-1

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Sensitive Cardiac Troponins: Could They Be New Biomarkers in Pediatric Pulmonary Hypertension Due to Congenital Heart Disease?

Abstract

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

A De Novo Novel Nonsense Mutation of GATA4 is Responsible for a Patient with Atrial Septal Defect

Inefficient Ventriculoarterial Coupling in Fontan Patients: A Cardiac Magnetic Resonance Study

Cardiac Function Assessments in Left Bochdalek’s Hernia: Clinical Relevance

Routine Cardiac Catheterization Prior to Fontan Operation: Is It a Necessity?

Correlation of Symptoms with Bronchoscopic Findings in Children with a Prenatal Diagnosis of a Right Aortic Arch and Left Arterial Duct

Prolonged PR Interval at Birth Predicting the High Occurrence of Fatal Atrioventricular Block in Hypoplastic Left Heart Syndrome

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie